In Vitro and In Vivo Activity of a Novel Locked Nucleic Acid (LNA)-Inhibitor-miR-221 against Multiple Myeloma Cells

• Maria Teresa Di Martino ,

  Contributed equally to this work with: Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio

  Affiliations Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Annamaria Gullà ,

  Contributed equally to this work with: Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Maria Eugenia Gallo Cantafio ,

  Contributed equally to this work with: Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Emanuela Altomare,

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Nicola Amodio,

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Emanuela Leone,

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Eugenio Morelli,

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Santo Giovanni Lio,

  Affiliation Pathology Unit, “Giovanni Paolo II” Hospital, Lamezia Terme, Catanzaro, Italy

  ⨯
• Daniele Caracciolo,

  Affiliation Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Marco Rossi,

  Affiliations Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Niels M. Frandsen,

  Affiliation Exiqon A/S, Vedbaek, Denmark

  ⨯
• Pierosandro Tagliaferri,

  Affiliations Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy

  ⨯
• Pierfrancesco Tassone

  * E-mail: tassone@unicz.it

  Affiliations Department of Experimental and Clinical Medicine, Magna Graecia University and Medical Oncology Unit, Salvatore Venuta University Campus, Catanzaro, Italy, T. Campanella Cancer Center, Salvatore Venuta University Campus, Catanzaro, Italy, Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, United States of America

  ⨯